Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis

Rheumatology
Carmel StoberDeepak Jadon

Abstract

To evaluate TNF-α inhibitor (TNFi) persistence when used as first- or second-line biologic therapy for the management of PsA, and to determine baseline clinical and laboratory parameters associated with TNFi persistence. A retrospective single-centre cohort study was performed on all patients with PsA initiated on TNFi therapy between 2003 and 2015. Demographic, clinical and laboratory characteristics were compared with TNFi persistence, using Kaplan-Meier survival and Cox proportional hazards models. One hundred and eighty-eight patients with PsA were prescribed TNFi therapy as first-line biologic therapy over a period of 635 person-years [46% male, mean (s.d.) age 47.3 (11.4) years; median (interquartile range) disease duration 11 (7-16) years]. At 12 months of follow-up 79% of patients persisted with TNFi therapy, and 73% at 24 months. Of those discontinuing TNFi, 35% stopped due to primary inefficacy, 22% secondary inefficacy and 43% adverse events. Multivariable analysis identified female sex (hazard ratio (HR) 2.57; 95% CI: 1.26, 5.24; P = 0.01) and the presence of metabolic syndrome-related co-morbidities (HR = 2.65, 95% CI: 1.24, 5.69; P = 0.01) as predictors of lower persistence. Of 32 cases treated with a second TNFi,...Continue Reading

References

Jul 13, 2004·Arthritis and Rheumatism·Philip J MeaseWayne Tsuji
Jan 29, 2005·Annals of the Rheumatic Diseases·C AntoniUNKNOWN IMPACT 2 Trial Investigators
Oct 4, 2005·Arthritis and Rheumatism·Philip J MeaseUNKNOWN Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Mar 2, 2006·Arthritis Research & Therapy·Juan J Gomez-ReinoUNKNOWN BIOBADASER Group
Feb 13, 2013·Nature Reviews. Rheumatology·Pauline A van SchouwenburgGerrit Jan Wolbink
Apr 9, 2013·Annals of the Rheumatic Diseases·Karen Minde FagerliTore K Kvien
Aug 29, 2013·Journal of the American Academy of Dermatology·Philip J MeaseDaniel Alvarez
Nov 17, 2014·The Journal of Rheumatology·Michael ZisapelOri Elkayam

❮ Previous
Next ❯

Citations

Mar 21, 2019·Current Rheumatology Reports·Ippei MiyagawaYoshiya Tanaka
Apr 30, 2019·Expert Review of Clinical Immunology·Carlo Selmi, M Eric Gershwin
Jun 14, 2019·Expert Review of Clinical Immunology·Michael Ruberson Ribeiro da SilvaFrancisco de Assis Acurcio
Apr 21, 2020·Immunological Medicine·Ippei Miyagawa, Yoshiya Tanaka
Apr 15, 2020·Clinical Rheumatology·A B AzuagaUNKNOWN ESPOCAT group
Oct 8, 2020·Nature Reviews. Rheumatology·Deepak R JadonOliver FitzGerald
Jan 8, 2021·Rheumatology Advances in Practice·Kirk GealeElke Theander
Jan 11, 2021·Rheumatology International·Sonal GuptaSizheng Steven Zhao
Jan 31, 2021·Arthritis Research & Therapy·Amir HaddadDevy Zisman
Jul 1, 2021·Rheumatology International·Lourdes Mateo SoriaAlejandro Olivé-Marqués
Nov 18, 2021·Expert Opinion on Pharmacotherapy·Hasan Tahir, Simran Grewal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.